8-K
filed February 25, 2025, 6:59 PM ET
ticker ABUS
CIK 0001447028
leadership
confidence high
sentiment neutral
materiality 0.65
Arbutus appoints Roivant-affiliated CEO and new board after all prior directors resign
Arbutus Biopharma Corp
- All seven directors resigned Feb 24; board reduced to five with new appointees including Roivant affiliates.
- Lindsay Androski named President and CEO, replacing interim CEO McElhaugh; she also serves as board chair.
- Androski receives $515k salary, 45% target bonus, and ~$750k option grant; three new directors are from Roivant.
- Company will pause investor meetings to review strategic options for hepatitis B pipeline and development plans.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Daniel Burgess resigned as Director at Arbutus Biopharma Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
Daniel Burgess
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.85
Lindsay Androski was appointed as Chief Executive Officer at Arbutus Biopharma Corp.
- Role
- Chief Executive Officer
Exact text from the filing
Ms. Androski, as Chief Executive Officer of the Company, will not receive compensation for her service as a director.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
James Meyers resigned as Director at Arbutus Biopharma Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
James Meyers
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard C. Henriques resigned as Director at Arbutus Biopharma Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
Richard C. Henriques
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Frank Torti resigned as Director at Arbutus Biopharma Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
Frank Torti, M.D., chairperson of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Melissa V. Rewolinski resigned as Director at Arbutus Biopharma Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
Melissa V. Rewolinski, Ph.D.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Keith Manchester resigned as Director at Arbutus Biopharma Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
Keith Manchester, M.D.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Lindsay Androski was appointed as Chairperson of the Board at Arbutus Biopharma Corp.
- Action
- appointed
- Role
- Chairperson of the Board
Exact text from the filing
appointed Ms. Androski as chairperson of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael J. McElhaugh resigned as Director at Arbutus Biopharma Corp.
- Action
- resigned
- Role
- Director
Exact text from the filing
Michael J. McElhaugh
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.